We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » La Jolla Gets Orphan Designation for Two Compounds for Muscle Disorder
La Jolla Gets Orphan Designation for Two Compounds for Muscle Disorder
The FDA has granted orphan drug designation to La Jolla Pharmaceutical for two novel compounds to treat fibrodysplasia ossificans progressiva, a genetic mutation that turns muscle into bone.